Miscellaneous news

An Insider’s View: Report on the Finnish Life Sciences Industry

Aalto University
University of Helsinki
Stanford University

Anne-Sisko Patana, Tamara Carleton, Kirsi Polvinen, Laura Kanto, Hanna Nordlund, Jussi Pihlajamaa, Pekka Berg

Introduction

This study provides several benefits to practitioners and researchers in the biotech field, as well as others looking for greater insight into Finnish biotech innovation. These benefits are explained below.

Read more...

The Perceived Value-added of Venture Capital Investors: Evidence from Finnish biotechnology industry

ETLA publication no 1030, 2006

Mari Maunula

Abstract

This study focuses on the non-financial value-added of venture capital investors (VCs) as perceived by the CEOs of Finnish biotechnology companies. It pays attention to differences in the value-added between informal venture capitalists, private sector venture capitalists and public sector venture capital organizations. In addition, this study pays attention to value-adding mechanisms which venture capitalists use in developing their portfolio companies and factors which influence the perceived value-added.

Read more...

Coaching small biotech companies into success: The value-adding function of VC

ETLA publication no 1032, 2006

Terttu Luukkonen
Mari Maunula

Abstract

The paper reports an empirical study on the non-financial value-added provided by Venture Capital investors to their investee firms. This study will use a four-class grouping of the various non-financial value-adding capabilities provided by VC firms, namely, scouting, monitoring, signalling and value-adding services. The study examines biotechnology industry in Finland.

Read more...

Promoting innovation by tax incentives—A review of strategies and their importance to biotech growth

Supported by European Commission Specific Support Action, 6th Framework Program

June 2006

Introduction

This report provides an overview of tax incentives for R&D as they exist today. More specifically, it presents a thorough comparison of the tax incentive programs that are presently in place in four countries: Canada, France, Norway and the UK. The report will hopefully give guidance in implementation of tax incentives in other countries, with a view to supporting the development of biotechnology companies and R&D-intensive companies in other industries.

Read more...

European Biotech industry figures show signs of chronic under-funding

Critical I comparative study for EuropaBio

John Hodgson, 2006

Introduction

The latest figures published today compares biotechnology sectors across some eighteen European nations and the USA.

The report finds that the European and the US biotechnology industries both have around 2000 companies, but the US sector employs nearly twice as many people, spends around three times as much on research and development, has twice the number of employees involved in research and development, raises over twice as much venture capital, and has access to 10 times as much debt finance. It earns twice as much revenue.

Read more...